Shots:
- The US FDA has approved Zycubo (copper histidinate) for the treatment of pediatric patients with Menkes disease
- Approval was supported by clinical data showing improved OS with early Zycubo treatment vs an untreated external control, reflecting ~80% reduction in the risk of death & a mOS of 177.1 vs 17.6mos.
- Zycubo is a bioavailable copper replacement therapy for Menkes disease, delivered as a daily SC injectable copper histidinate to supply elemental copper
Ref: PRnewswire | Image: Sentynl | Press Release
Related News: Zydus Partners with Bioeq for US Commercialization of Nufymco (Biosimilar, Lucentis)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
